JP6387019B2 - ジケトピペラジンおよびジケトピペラジン含有組成物を生産するための方法 - Google Patents

ジケトピペラジンおよびジケトピペラジン含有組成物を生産するための方法 Download PDF

Info

Publication number
JP6387019B2
JP6387019B2 JP2015556207A JP2015556207A JP6387019B2 JP 6387019 B2 JP6387019 B2 JP 6387019B2 JP 2015556207 A JP2015556207 A JP 2015556207A JP 2015556207 A JP2015556207 A JP 2015556207A JP 6387019 B2 JP6387019 B2 JP 6387019B2
Authority
JP
Japan
Prior art keywords
albumin
dkp
stream
hsa
dpp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015556207A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016511238A5 (https=
JP2016511238A (ja
Inventor
バー−オー、デイビッド
Original Assignee
アンピオ ファーマシューティカルズ，インコーポレイテッド
アンピオ ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンピオ ファーマシューティカルズ，インコーポレイテッド, アンピオ ファーマシューティカルズ，インコーポレイテッド filed Critical アンピオ ファーマシューティカルズ，インコーポレイテッド
Publication of JP2016511238A publication Critical patent/JP2016511238A/ja
Publication of JP2016511238A5 publication Critical patent/JP2016511238A5/ja
Application granted granted Critical
Publication of JP6387019B2 publication Critical patent/JP6387019B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
JP2015556207A 2013-02-01 2014-02-03 ジケトピペラジンおよびジケトピペラジン含有組成物を生産するための方法 Expired - Fee Related JP6387019B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361759922P 2013-02-01 2013-02-01
US61/759,922 2013-02-01
PCT/US2014/014478 WO2014121210A1 (en) 2013-02-01 2014-02-03 Methods for producing diketopiperazines and compositions containing diketopiperazines

Publications (3)

Publication Number Publication Date
JP2016511238A JP2016511238A (ja) 2016-04-14
JP2016511238A5 JP2016511238A5 (https=) 2017-03-09
JP6387019B2 true JP6387019B2 (ja) 2018-09-05

Family

ID=51263032

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015556207A Expired - Fee Related JP6387019B2 (ja) 2013-02-01 2014-02-03 ジケトピペラジンおよびジケトピペラジン含有組成物を生産するための方法

Country Status (15)

Country Link
US (1) US20150366932A1 (https=)
EP (1) EP2950811A4 (https=)
JP (1) JP6387019B2 (https=)
KR (1) KR20150114984A (https=)
CN (1) CN105188737A (https=)
AU (1) AU2014212095B2 (https=)
BR (1) BR112015017958A2 (https=)
CA (1) CA2900050A1 (https=)
EA (1) EA030414B1 (https=)
HK (1) HK1214772A1 (https=)
IL (1) IL240125A0 (https=)
MX (1) MX2015009908A (https=)
PH (1) PH12015501705A1 (https=)
SG (2) SG10201706213RA (https=)
WO (1) WO2014121210A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011676A2 (en) 2000-08-04 2002-02-14 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
EP1622633B1 (en) 2003-05-15 2016-02-24 Ampio Pharmaceuticals, Inc. Treatment of t-cell mediated diseases
EP2300011A4 (en) 2008-05-27 2012-06-20 Dmi Life Sciences Inc THERAPEUTIC PROCESSES AND COMPOUNDS
EP3721884A1 (en) 2011-10-10 2020-10-14 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease with da-dkp (= aspartyl-alanyl diketopiperazine)
SG10201608087WA (en) 2011-10-10 2016-11-29 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
CN103841974A (zh) 2011-10-28 2014-06-04 安皮奥制药股份有限公司 鼻炎的治疗
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
CA2958080A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
US10426796B2 (en) * 2016-06-13 2019-10-01 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
US10456423B2 (en) 2016-06-13 2019-10-29 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
WO2021016186A1 (en) * 2019-07-19 2021-01-28 University Of Utah Research Foundation Rapid sperm separation based on sperm morphology and motility
WO2021163693A1 (en) * 2020-02-16 2021-08-19 Pur Biologics, Inc. Methods of manufacturing extracellular matrix using aspartyl alanyl diketopiperazine (da-dkp)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2092556A5 (https=) * 1970-04-02 1972-01-21 Snam Progetti
US5561115A (en) * 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
US5811241A (en) * 1995-09-13 1998-09-22 Cortech, Inc. Method for preparing and identifying N-substitued 1,4-piperazines and N-substituted 1,4-piperazinediones
JP2000005569A (ja) * 1998-06-24 2000-01-11 Asahi Chem Ind Co Ltd 直列多段濾過法
WO2002011676A2 (en) * 2000-08-04 2002-02-14 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
EP1622633B1 (en) * 2003-05-15 2016-02-24 Ampio Pharmaceuticals, Inc. Treatment of t-cell mediated diseases
CN1791420A (zh) * 2003-05-15 2006-06-21 Dmi生物科学公司 T－细胞介导的疾病的治疗
US7790039B2 (en) * 2003-11-24 2010-09-07 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for stem cell enrichment
US20050197496A1 (en) * 2004-03-04 2005-09-08 Gtc Biotherapeutics, Inc. Methods of protein fractionation using high performance tangential flow filtration
MX2007002085A (es) * 2004-08-20 2007-07-19 Prometic Biosciences Ltd Esquemas de aislamiento y purificacion consecutivos de proteinas mediante cromatografia de afinidad.
CA2776241A1 (en) * 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
WO2012174472A1 (en) * 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
EP3721884A1 (en) * 2011-10-10 2020-10-14 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease with da-dkp (= aspartyl-alanyl diketopiperazine)
SG10201608087WA (en) * 2011-10-10 2016-11-29 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
CN103841974A (zh) * 2011-10-28 2014-06-04 安皮奥制药股份有限公司 鼻炎的治疗

Also Published As

Publication number Publication date
EP2950811A4 (en) 2016-06-08
CA2900050A1 (en) 2014-08-07
PH12015501705A1 (en) 2015-10-12
BR112015017958A2 (pt) 2017-07-11
HK1214772A1 (zh) 2016-08-05
EA030414B1 (ru) 2018-08-31
AU2014212095B2 (en) 2018-07-26
MX2015009908A (es) 2015-09-24
EP2950811A1 (en) 2015-12-09
CN105188737A (zh) 2015-12-23
WO2014121210A1 (en) 2014-08-07
US20150366932A1 (en) 2015-12-24
EA201500783A1 (ru) 2016-05-31
AU2014212095A1 (en) 2015-09-10
SG11201505715RA (en) 2015-08-28
JP2016511238A (ja) 2016-04-14
KR20150114984A (ko) 2015-10-13
IL240125A0 (en) 2015-09-24
SG10201706213RA (en) 2017-09-28

Similar Documents

Publication Publication Date Title
JP6387019B2 (ja) ジケトピペラジンおよびジケトピペラジン含有組成物を生産するための方法
CN103347530B (zh) 糖尿病的治疗或预防剂
RS57292B1 (sr) Ace2 polipeptid
JP5366161B2 (ja) Ｔｎｆアンタゴニスト及びそれを有効成分とするｔｎｆ阻害剤
CN118203658A (zh) 一种重组抗Claudin18.2全人源单克隆抗体注射液制剂及制备方法
CN1318069A (zh) 因子VIIa抑制剂
Koroleva et al. Semax as a universal drug for therapy and research
JPWO2006115274A1 (ja) 骨髄赤血球前駆細胞分化促進剤
JP2024105444A (ja) 治療剤の制御放出用組成物
JP2009508822A (ja) 慢性腎症の処置のためのｈ因子およびその製造
CN112409450B (zh) TIGIT-IgV的亲和剂及其应用
JP2001518450A (ja) 一酸化窒素生成の調節方法
JP2916947B2 (ja) Ｃｐｂ―ｉの安定化方法及び製剤組成物
EP3558343A1 (en) Methods of administering hepcidin
US20250304655A1 (en) Expression System for Producing a Recombinant Haptoglobin (Hp) Beta Chain
EP4279066A1 (en) Ophthalmic composition including tanfanercept and exhibiting stability without use of stabilizer
JP2916948B2 (ja) Ｃｐｂ―ｉの安定化方法及びこの製剤組成物
WO2026006884A1 (en) Modulators of fxii-upar
JPWO2006118196A1 (ja) Ｄｐｐ４阻害剤及びその医薬用途
KR20200038309A (ko) 폰 빌레브란트 인자의 바이러스 여과 방법
JPH05178756A (ja) 肝疾患の予防・治療薬
JPH0482898A (ja) 新規なペプチド及びアンジオテンシン変換酵素阻害剤
Groot et al. Lactoferrin prevents dendritic cell-mediated HIV-1 transmission by blocking the DC-SIGN—gp120 interaction
EP3335729A1 (en) Etanercept composition having improved stability
JPH0214034B2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180330

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180717

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180810

R150 Certificate of patent or registration of utility model

Ref document number: 6387019

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees